Saturday, November 21, 2015 12:44:56 PM
Been watching this stock for just a few months.
Seems to me the science is doable and all three clinical candidates seem to have activity with great safety.
Just listened to the last conference webcast and seems the next potential inflection point is going to be in January when more data on Archexin comes out. Also if all goes well, Supinoxin & 3117 Phase II early next year.
At 0.41 PPS seems a good time to get in too, however expecting investors with itchy feet to keep making small sales until we get closer to the Jan data readout.
One question I have for those that have been here for longer than myself. I see that there has been discussion of the potential R/S.
1. Do we think this is likely to happen?
2. When would this be expected to happen? Is there an expiration on when the R/S can happen?
Hope this finds everyone well and looking forward to further discussions on this board.
Spidey
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM